Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730369 | 0.83 | — | — | |
| SCHEMBL10202107 | 0.81 | DPP4 (0.31) | KDM4EDPP4 | |
| SCHEMBL4742954 | 0.80 | DPP4 (0.33) | DPP4 | |
| SCHEMBL13713515 | 0.79 | ALDH1A1 (0.39) | CNR2GRIN2BKDM5AKDM4CTSHR | |
| SCHEMBL22964983 | 0.77 | DPP4 (0.35) | CNR2GRIN2BKDM5AKDM4CTSHR | |
| SCHEMBL11847774 | 0.77 | ALDH1A1 (0.37) | CNR2GRIN2BKDM5AKDM4CTSHR | |
| SCHEMBL11892711 | 0.76 | L3MBTL1 (0.36) | CNR2GRIN2BKDM5AKDM4CTSHR | |
| SCHEMBL19432459 | 0.74 | DPP4 (0.39) | CNR2GRIN2BTSHRNFKB1CYP2C19 | |
| SCHEMBL14930636 | 0.74 | ALDH1A1 (0.42) | CNR2TSHRCYP2C19 | |
| SCHEMBL11890349 | 0.74 | CYP2C19 (0.33) | CNR2GRIN2BKDM5AKDM4CTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | CNR2 3719/4885GRIN2B 4825/4885KDM4E 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.